Zentek’s Triera Launches CRO Services Under 20-Year Exclusive McMaster Aptamer License
Zentek’s subsidiary Triera Biosciences will begin offering contract research organization services for custom aptamer discovery, biosensor engineering and machine-learning classification under a 20-year exclusive license from McMaster University. Its asset-light model retains IP ownership while targeting diagnostic markets for influenza A, SARS-CoV-2, VEGF and syphilis across North America and Europe.
1. Launch of CRO Services
Zentek’s wholly owned subsidiary Triera Biosciences is rolling out contract research organization offerings for custom aptamer discovery, biosensor integration and optional machine-learning classification support, serving pharmaceutical, biotech and diagnostics firms in Canada, the United States and Europe.
2. Exclusive McMaster License and Platform Capabilities
Triera holds a worldwide, royalty-bearing 20-year license from McMaster University for aptamer applications developed via SELEX methodology, enabling sub-nanomolar affinity aptamer discovery on targets including influenza A, SARS-CoV-2, VEGF, syphilis and others under development.
3. Asset-Light Model and Market Opportunity
Operating on a client-funded, IP-retained basis, Triera aims to generate earlier, predictable revenue while addressing high-growth diagnostic markets, such as a projected USD 155 billion cancer diagnostics sector by 2030 and a USD 2.5 billion+ STI diagnostics market by 2032.